Kirsten K. Ness
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kirsten K. Ness has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Melissa M. Hudson
Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA
8 shared publications - Leslie L. Robison
Department of Epidemiology and Cancer Control, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA
7 shared publications Deo Kumar Srivastava
St. Jude Children's Research Hospital, Memphis, TN
3 shared publications- Deo Kumar Srivastava
Department of Biostatistics, St. Jude Children’s Research Hospital, Memphis, USA
3 shared publications James G. Gurney
Child Health and Evaluation Unit (CHEAR), Department of Pediatrics, University of Michigan, Ann Arbor, Michigan 48109-0456
3 shared publications- Matthew J. Ehrhardt
Department of Oncology, St Jude Children's Research Hospital, Memphis, TN
3 shared publications
Latest Publications
- 20 June 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (18_suppl) , LBA10500
Temporal trends in chronic disease among survivors of childhood cancer diagnosed across three decades: A report from the Childhood Cancer Survivor Study (CCSS).
LBA10500 Background: Modifications in childhood cancer treatments in recent decades have contributed to reductions in late mortality among 5-year survivors. We used the recently expanded CCSS cohort to investigate whether these changes have also reduced the incidence of chronic disease. Methods: We evaluated the incidence of severe, disabling/life-threatening, or fatal chronic health conditions (Common Terminology Criteria for Adverse Events, CTCAE grades 3-5) among 5-year survivors diagnosed prior to age 21 years from 1970 through 1999. We calculated the 15-year cumulative incidence of chronic health conditions by decade of cancer diagnosis and compared risk across decades using Cox regression to estimate hazard ratios (HR) and 95% confidence intervals (CI). Results: Among 23,601 survivors, median age 28 years (range 5-63), 21 years from diagnosis (5-43), the 15-year cumulative incidence of grade 3-5 conditions decreased from 12.7% in survivors diagnosed in the 1970s to 10.1% and 8.8% in those diagnosed in the 1980s and 1990s (per 10 years, HR 0.84 [95% CI = 0.80-0.89]). The association with diagnosis decade was attenuated (HR 0.92 [0.85-1.00]) when detailed treatment data were included in the model, indicating that treatment reductions mediated risk. Adjusted for sex and attained age, significant reduction in risk over time was found among survivors of Wilms tumor (HR 0.57 [0.46-0.70]), Hodgkin lymphoma (HR 0.75 [0.65-0.85]), astrocytoma (HR 0.77 [0.64-0.92]), non-Hodgkin lymphoma (HR 0.79 [0.63-0.99]), and acute lymphoblastic leukemia (HR 0.86 [0.76-0.98]). Decreases were largely driven by a reduced incidence of endocrine conditions (1970s: 4.0% v. 1990s:1.6%; HR 0.66 [0.59-0.73]) and subsequent malignant neoplasms (1970s: 2.4% v. 1990s: 1.6%; HR 0.85 [0.76-0.96]). Significant reductions were also found for gastrointestinal (HR 0.80 [0.66-0.97]) and neurological conditions (HR 0.77 [0.65-0.91]), but not cardiac or pulmonary conditions. Conclusions: Changes in childhood cancer treatment protocols have not only extended lifespan for many survivors, but have also reduced the incidence of serious chronic morbidity in this population.
- 20 June 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (18_suppl) , LBA10500
Temporal trends in chronic disease among survivors of childhood cancer diagnosed across three decades: A report from the Childhood Cancer Survivor Study (CCSS).
LBA10500 Background: Modifications in childhood cancer treatments in recent decades have contributed to reductions in late mortality among 5-year survivors. We used the recently expanded CCSS cohort to investigate whether these changes have also reduced the incidence of chronic disease. Methods: We evaluated the incidence of severe, disabling/life-threatening, or fatal chronic health conditions (Common Terminology Criteria for Adverse Events, CTCAE grades 3-5) among 5-year survivors diagnosed prior to age 21 years from 1970 through 1999. We calculated the 15-year cumulative incidence of chronic health conditions by decade of cancer diagnosis and compared risk across decades using Cox regression to estimate hazard ratios (HR) and 95% confidence intervals (CI). Results: Among 23,601 survivors, median age 28 years (range 5-63), 21 years from diagnosis (5-43), the 15-year cumulative incidence of grade 3-5 conditions decreased from 12.7% in survivors diagnosed in the 1970s to 10.1% and 8.8% in those diagnosed in the 1980s and 1990s (per 10 years, HR 0.84 [95% CI = 0.80-0.89]). The association with diagnosis decade was attenuated (HR 0.92 [0.85-1.00]) when detailed treatment data were included in the model, indicating that treatment reductions mediated risk. Adjusted for sex and attained age, significant reduction in risk over time was found among survivors of Wilms tumor (HR 0.57 [0.46-0.70]), Hodgkin lymphoma (HR 0.75 [0.65-0.85]), astrocytoma (HR 0.77 [0.64-0.92]), non-Hodgkin lymphoma (HR 0.79 [0.63-0.99]), and acute lymphoblastic leukemia (HR 0.86 [0.76-0.98]). Decreases were largely driven by a reduced incidence of endocrine conditions (1970s: 4.0% v. 1990s:1.6%; HR 0.66 [0.59-0.73]) and subsequent malignant neoplasms (1970s: 2.4% v. 1990s: 1.6%; HR 0.85 [0.76-0.96]). Significant reductions were also found for gastrointestinal (HR 0.80 [0.66-0.97]) and neurological conditions (HR 0.77 [0.65-0.91]), but not cardiac or pulmonary conditions. Conclusions: Changes in childhood cancer treatment protocols have not only extended lifespan for many survivors, but have also reduced the incidence of serious chronic morbidity in this population.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 10560
Relationship between the cumulative burden (CB) of chronic health conditions (CHC) and health-related quality of life (HRQoL) among childhood cancer survivors (CCS): The St. Jude Lifetime (SJLIFE) cohort.
10560 Background: Adult CCS experience an excess burden of CHC. The association between disease burden (estimated using CB) and HRQoL has not been extensively assessed. Methods: 2878 CCS (mean [range] age 32.1 [18.3-66.2] years; time from diagnosis 25.0 [10.2-51.0] years) were enrolled in SJLIFE (eligibility: survived >10 years and >18 years of age) and clinically evaluated for 168 graded CHC using the St. Jude modified Common Terminology Criteria for Adverse Events. HRQoL was assessed using the Short Form 36 survey and categorized into Low (< -0.5 SDs), Average (-0.5 to 0.5 SDs), and High (> 0.5 SDs) subgroups from the Physical and Mental Component Summary (PCS, MCS) and Vitality Scale using cohort age- and sex-specific values. CB (average number of grade 3-4 [severe/life-threatening] CHC/survivor) for each CHC was calculated and summed for each HRQoL subgroup. Results: Survivors with low PCS had, on average, more CHC CB compared to those with High and Average PCS. Higher CHC CB was also associated with poorer Vitality and MCS, but the differences in effect size were smaller than PCS. When CB for each of the 3 HRQoL scores were compared by subgroups across 12 organ systems and subsequent neoplasms, CB at age 50 differed significantly (p
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 10560
Relationship between the cumulative burden (CB) of chronic health conditions (CHC) and health-related quality of life (HRQoL) among childhood cancer survivors (CCS): The St. Jude Lifetime (SJLIFE) cohort.
10560 Background: Adult CCS experience an excess burden of CHC. The association between disease burden (estimated using CB) and HRQoL has not been extensively assessed. Methods: 2878 CCS (mean [range] age 32.1 [18.3-66.2] years; time from diagnosis 25.0 [10.2-51.0] years) were enrolled in SJLIFE (eligibility: survived >10 years and >18 years of age) and clinically evaluated for 168 graded CHC using the St. Jude modified Common Terminology Criteria for Adverse Events. HRQoL was assessed using the Short Form 36 survey and categorized into Low (< -0.5 SDs), Average (-0.5 to 0.5 SDs), and High (> 0.5 SDs) subgroups from the Physical and Mental Component Summary (PCS, MCS) and Vitality Scale using cohort age- and sex-specific values. CB (average number of grade 3-4 [severe/life-threatening] CHC/survivor) for each CHC was calculated and summed for each HRQoL subgroup. Results: Survivors with low PCS had, on average, more CHC CB compared to those with High and Average PCS. Higher CHC CB was also associated with poorer Vitality and MCS, but the differences in effect size were smaller than PCS. When CB for each of the 3 HRQoL scores were compared by subgroups across 12 organ systems and subsequent neoplasms, CB at age 50 differed significantly (p
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 10564
Endothelial dysfunction in adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort study.
10564 Background: Endothelial dysfunction, as an indicator of vascular disease in childhood cancer survivors (CCS) has not been widely studied. Methods: Markers of vascular inflammation (high sensitivity C-reactive protein [hsCRP]), hemostasis (fibrinogen), activation (endothelial cell expression of vascular cell adhesion molecule [VCAM-1]) and functional testing (large/small artery elasticity [L/SAE], pulse wave velocity [PWV]) were assessed in 200 CCS, ≥10 years from diagnosis, and 192 age/gender matched healthy controls. Exclusion criteria included: inflammatory processes, use of anti-inflammatory or cardiovascular medications, or pregnancy. Differences were assessed by adjusted multivariable linear regression. Results: CCS (53% male) of leukemia/lymphoma (59%), central nervous system tumors (6%), sarcomas (11.5%), embryonal tumors (22.5%), and other (1%) had a mean age at diagnosis 7.3 years (SD ±5.7). CCS and controls did not differ in current age (mean 34.1 ±9.2 vs. 33.5 years ±9.8), body mass index, smoking, mean systolic (124 mm Hg ±11.7 vs. 123 ±11.9) or diastolic blood pressure (73 ±9.5 vs. 71 ±9.5). Fasting low- (110 mg/dl ±31 vs. 102 ±30) and high-density (52 ±16 vs. 56 ±18) cholesterol levels differed between survivors and controls (p
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 10564
Endothelial dysfunction in adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort study.
10564 Background: Endothelial dysfunction, as an indicator of vascular disease in childhood cancer survivors (CCS) has not been widely studied. Methods: Markers of vascular inflammation (high sensitivity C-reactive protein [hsCRP]), hemostasis (fibrinogen), activation (endothelial cell expression of vascular cell adhesion molecule [VCAM-1]) and functional testing (large/small artery elasticity [L/SAE], pulse wave velocity [PWV]) were assessed in 200 CCS, ≥10 years from diagnosis, and 192 age/gender matched healthy controls. Exclusion criteria included: inflammatory processes, use of anti-inflammatory or cardiovascular medications, or pregnancy. Differences were assessed by adjusted multivariable linear regression. Results: CCS (53% male) of leukemia/lymphoma (59%), central nervous system tumors (6%), sarcomas (11.5%), embryonal tumors (22.5%), and other (1%) had a mean age at diagnosis 7.3 years (SD ±5.7). CCS and controls did not differ in current age (mean 34.1 ±9.2 vs. 33.5 years ±9.8), body mass index, smoking, mean systolic (124 mm Hg ±11.7 vs. 123 ±11.9) or diastolic blood pressure (73 ±9.5 vs. 71 ±9.5). Fasting low- (110 mg/dl ±31 vs. 102 ±30) and high-density (52 ±16 vs. 56 ±18) cholesterol levels differed between survivors and controls (p
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 10523
Cumulative burden of chronic disease in adult survivors of childhood cancer: The St. Jude Lifetime (SJLIFE) cohort.
10523 Background: A substantial proportion of childhood cancer survivors develop chronic health conditions. However, the cumulative burden (CB) of multiple organ system morbidity among survivors has not been described. Methods: 3026 childhood cancer survivors (mean age 35.3 yrs, range 19-68; time from diagnosis 27.0 yrs, range 11-53) were enrolled in the SJLIFE cohort (eligibility: survived > 10 yrs and > 18 yrs of age) and clinically evaluated for 166 chronic health conditions. Results from prospective and retrospective clinical assessments were used to grade outcomes using a modified Common Terminology Criteria for Adverse Events. Mean cumulative count per 100 survivors was used to estimate CB with 95% confidence intervals (CI). Results: At 35 yrs post-diagnosis the estimated cumulative incidence of survivors experiencing a Grade 1-4 (mild to life-threatening) or Grade 3-4 (severe or life-threatening) chronic condition was 98.5% and 87.2%, respectively. At 35 yrs, the estimated CB was 1,065 (CI 1029-1100) Grade 1-4 conditions per 100 survivors and 300 (CI 285-314) Grade 3-4 conditions per 100 survivors. The CB for Grade 1-4 conditions ranged from 566 per 100 retinoblastoma survivors to 1,741 per 100 CNS survivors (Table). Substantial increases in Grade 1-4 CB occurred from 10 and 20 yrs to 35 yrs post-diagnosis, rising from 138 (CI 131-145) and 417 (CI 401-435) to 1,065 per 100 survivors, respectively. Conclusions: At 35 yrs from initial cancer diagnosis, 99% of survivors will experience at least one chronic condition. However, the true impact of surviving cancer is reflected in the 35 year CB, when it is estimated that, on average, a survivor will experience 11 non-fatal chronic health conditions including an average of 3 severe or life-threatening conditions.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 10523
Cumulative burden of chronic disease in adult survivors of childhood cancer: The St. Jude Lifetime (SJLIFE) cohort.
10523 Background: A substantial proportion of childhood cancer survivors develop chronic health conditions. However, the cumulative burden (CB) of multiple organ system morbidity among survivors has not been described. Methods: 3026 childhood cancer survivors (mean age 35.3 yrs, range 19-68; time from diagnosis 27.0 yrs, range 11-53) were enrolled in the SJLIFE cohort (eligibility: survived > 10 yrs and > 18 yrs of age) and clinically evaluated for 166 chronic health conditions. Results from prospective and retrospective clinical assessments were used to grade outcomes using a modified Common Terminology Criteria for Adverse Events. Mean cumulative count per 100 survivors was used to estimate CB with 95% confidence intervals (CI). Results: At 35 yrs post-diagnosis the estimated cumulative incidence of survivors experiencing a Grade 1-4 (mild to life-threatening) or Grade 3-4 (severe or life-threatening) chronic condition was 98.5% and 87.2%, respectively. At 35 yrs, the estimated CB was 1,065 (CI 1029-1100) Grade 1-4 conditions per 100 survivors and 300 (CI 285-314) Grade 3-4 conditions per 100 survivors. The CB for Grade 1-4 conditions ranged from 566 per 100 retinoblastoma survivors to 1,741 per 100 CNS survivors (Table). Substantial increases in Grade 1-4 CB occurred from 10 and 20 yrs to 35 yrs post-diagnosis, rising from 138 (CI 131-145) and 417 (CI 401-435) to 1,065 per 100 survivors, respectively. Conclusions: At 35 yrs from initial cancer diagnosis, 99% of survivors will experience at least one chronic condition. However, the true impact of surviving cancer is reflected in the 35 year CB, when it is estimated that, on average, a survivor will experience 11 non-fatal chronic health conditions including an average of 3 severe or life-threatening conditions.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 10574
Body composition among adult survivors of pediatric abdominal and pelvic tumors in the St. Jude Lifetime Cohort.
10574 Background: In the general population, adverse changes in body composition are associated with reduced physical function, metabolic impairment and mortality. However, little is known about changes in body composition among adult survivors of non-hematological malignancies diagnosed in childhood. Methods: Participants included 347 long-term survivors with a history of abdominal or pelvic tumors. Using dual X-ray absorptiometry, relative lean mass (LM) was calculated by dividing lean mass by height (m2) and calculating race- age- and sex-standardized z-scores using data from NHANES. Multiple linear regression, stratified by sex, was used to evaluate associations between treatment (abdominal/pelvic radiation, alkylators, anthracyclines), lifestyle factors (smoking, activity levels and daily caloric consumption) and LM. Results: The median age at follow-up was 29.6 (range: 18.7-55.1) years and median time from diagnosis was 24.2 (range: 10.7-50.0) years. Forty-four percent of participants had received abdominal/pelvic radiation. Fifty-eight percent and 51% of male and female survivors had a BMI ≥ 25 kg/m2, respectively. For survivors with BMI ≥ 25 kg/m2, LM did not differ significantly from normative data in males (z-score = 0.06 [±0.76], p = 0.462) and was increased relative to normative data in females (z-score = 0.24 [±0.91], p = 0.01). Among survivors with a BMI < 25 kg/m2, mean LM was reduced among both males (z-score = -1.70 [±1.11], p < 0.001) and females (z-score = -1.64 [±1.02], p < 0.001). In multivariable analyses, males survivors who were exposed to abdominal/pelvic radiation (Estimate = -1.10, standard error [SE] = 0.23, p < 0.001) or who smoked (Estimate = -0.53, SE = 0.23, p = 0.020) had an increased risk of low LM when compared to males not exposed to radiation or non-smokers. Only exposure to abdominal/pelvic radiation was associated with an increased risk of low LM among females (Estimate = -0.76, SE = 0.24, p = 0.002). Conclusions: Survivors with BMI < 25 kg/m2 have low LM compared to US normative data. Further studies are required to understand the impact of low LM on metabolic profile and physical function among survivors of pediatric solid tumors.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 10574
Body composition among adult survivors of pediatric abdominal and pelvic tumors in the St. Jude Lifetime Cohort.
10574 Background: In the general population, adverse changes in body composition are associated with reduced physical function, metabolic impairment and mortality. However, little is known about changes in body composition among adult survivors of non-hematological malignancies diagnosed in childhood. Methods: Participants included 347 long-term survivors with a history of abdominal or pelvic tumors. Using dual X-ray absorptiometry, relative lean mass (LM) was calculated by dividing lean mass by height (m2) and calculating race- age- and sex-standardized z-scores using data from NHANES. Multiple linear regression, stratified by sex, was used to evaluate associations between treatment (abdominal/pelvic radiation, alkylators, anthracyclines), lifestyle factors (smoking, activity levels and daily caloric consumption) and LM. Results: The median age at follow-up was 29.6 (range: 18.7-55.1) years and median time from diagnosis was 24.2 (range: 10.7-50.0) years. Forty-four percent of participants had received abdominal/pelvic radiation. Fifty-eight percent and 51% of male and female survivors had a BMI ≥ 25 kg/m2, respectively. For survivors with BMI ≥ 25 kg/m2, LM did not differ significantly from normative data in males (z-score = 0.06 [±0.76], p = 0.462) and was increased relative to normative data in females (z-score = 0.24 [±0.91], p = 0.01). Among survivors with a BMI < 25 kg/m2, mean LM was reduced among both males (z-score = -1.70 [±1.11], p < 0.001) and females (z-score = -1.64 [±1.02], p < 0.001). In multivariable analyses, males survivors who were exposed to abdominal/pelvic radiation (Estimate = -1.10, standard error [SE] = 0.23, p < 0.001) or who smoked (Estimate = -0.53, SE = 0.23, p = 0.020) had an increased risk of low LM when compared to males not exposed to radiation or non-smokers. Only exposure to abdominal/pelvic radiation was associated with an increased risk of low LM among females (Estimate = -0.76, SE = 0.24, p = 0.002). Conclusions: Survivors with BMI < 25 kg/m2 have low LM compared to US normative data. Further studies are required to understand the impact of low LM on metabolic profile and physical function among survivors of pediatric solid tumors.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 10524
Functional independence in adult survivors of pediatric CNS tumors: A report from the St. Jude lifetime cohort study.
10524 Background: Beyond survival, attainment of functional independence is the primary goal for adult survivors of pediatric CNS tumors. However, the prevalence of and risk factors for non-independence have not been examined. Methods: Functional independence was assessed in 306 survivors (95 astrocytoma, 77 medulloblastoma/PNET, 35 ependymoma, 99 other) with mean [SD] current age = 26.3 years[5.1] and years since diagnosis = 17.6[5.0]. Six indicators were used to identify classes of independence using latent class analysis: employment, independent living, assistance with personal care and routine needs, driving ability and marital status. Physical performance impairments were defined as scores <10th percentile of normative data. Quality of life was measured using the SF-36. Multinomial logistic regression estimated odds ratios (OR) and 95% confidence intervals (CI) for associations with functional independence. Treatment models were adjusted for age, sex, age at diagnosis, tumor location, and surgical resection. Physical performance models were adjusted for age, sex, race, IQ, and chronic health conditions (cardiac, pulmonary, endocrine, neurologic). Results: Three classes of functional independence were identified: 1) independent (40%), 2) moderately independent (34%), and non-independent (26%). In multivariable treatment models, craniospinal irradiation (OR=4.9, 95%, 2.0-11.9) and younger age at diagnosis (OR=0.81, 95% CI, 0.74-0.88) were associated with increased risk of non-independence. After covariate adjustment, limitations in aerobic capacity (OR = 6.2; 95% CI, 2.1-18.5), balance (OR = 3.1; 95% CI, 1.2-7.7), strength (OR = 4.6; 95% CI, 1.2-18.2), and adaptive abilities (OR = 13.3; 95% CI, 4.2-42.4) were associated with increased odds of non-independence. Non-independent survivors reported worse physical (OR=2.7, 95% CI, 1.5-5.2), social (OR=1.5, 95% CI, 1.0-2.9), and emotional (OR=1.4, 95% CI, 1.0-2.0) quality of life than functionally independent survivors. Conclusions: A substantial proportion of pediatric CNS tumor survivors are unable to function independently as adults. Interventions targeting physical performance deficits are needed.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 10524
Functional independence in adult survivors of pediatric CNS tumors: A report from the St. Jude lifetime cohort study.
10524 Background: Beyond survival, attainment of functional independence is the primary goal for adult survivors of pediatric CNS tumors. However, the prevalence of and risk factors for non-independence have not been examined. Methods: Functional independence was assessed in 306 survivors (95 astrocytoma, 77 medulloblastoma/PNET, 35 ependymoma, 99 other) with mean [SD] current age = 26.3 years[5.1] and years since diagnosis = 17.6[5.0]. Six indicators were used to identify classes of independence using latent class analysis: employment, independent living, assistance with personal care and routine needs, driving ability and marital status. Physical performance impairments were defined as scores <10th percentile of normative data. Quality of life was measured using the SF-36. Multinomial logistic regression estimated odds ratios (OR) and 95% confidence intervals (CI) for associations with functional independence. Treatment models were adjusted for age, sex, age at diagnosis, tumor location, and surgical resection. Physical performance models were adjusted for age, sex, race, IQ, and chronic health conditions (cardiac, pulmonary, endocrine, neurologic). Results: Three classes of functional independence were identified: 1) independent (40%), 2) moderately independent (34%), and non-independent (26%). In multivariable treatment models, craniospinal irradiation (OR=4.9, 95%, 2.0-11.9) and younger age at diagnosis (OR=0.81, 95% CI, 0.74-0.88) were associated with increased risk of non-independence. After covariate adjustment, limitations in aerobic capacity (OR = 6.2; 95% CI, 2.1-18.5), balance (OR = 3.1; 95% CI, 1.2-7.7), strength (OR = 4.6; 95% CI, 1.2-18.2), and adaptive abilities (OR = 13.3; 95% CI, 4.2-42.4) were associated with increased odds of non-independence. Non-independent survivors reported worse physical (OR=2.7, 95% CI, 1.5-5.2), social (OR=1.5, 95% CI, 1.0-2.9), and emotional (OR=1.4, 95% CI, 1.0-2.0) quality of life than functionally independent survivors. Conclusions: A substantial proportion of pediatric CNS tumor survivors are unable to function independently as adults. Interventions targeting physical performance deficits are needed.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 10571
Renal function after treatment for childhood cancer.
10571 Background: Childhood cancer survivors (CCS) are exposed to nephrotoxic treatments. We assessed renal function (RF), and factors associated with chronic kidney disease (CKD) in a large cohort of long-term CCS unexposed to abdominal irradiation. Methods: We evaluated 2,314 SJLIFE participants ( > 10 years (yrs) post-diagnosis, age ≥ 18 yrs) measuring serum sodium, potassium, magnesium, urinalysis (hematuria ≥ 5 RBC/hpf; proteinuria ≥ 1+ protein), and estimated glomerular filtration rate (eGFR) using the CKD Epidemiology Collaboration (CKD-EPI) equation. CKD was defined according to the National Kidney Foundation Kidney Disease Outcome Quality Initiative. Logistic regression, adjusting for length of follow-up, was used to estimate odds ratios (ORs) and 95% confidence intervals (CI) for the association between demographic and clinical factors, and CKD. Results: 1110(48%) survivors were female. 1920(83%) were non-Hispanic white. Median age at diagnosis-6.9 yrs (interquartile range [IQR] = 3.2-12.6), median age at RF evaluation-31 yrs (IQR = 25.3-37.0), and median elapsed time from diagnosis to evaluation-23 yrs (IQR = 17.3-29.4). 70(3.0%) were hypokalemic ( < 3.4 mmol/L or taking supplement), 39(1.7%) hypomagnesemic ( < 1.3 meq/dL or taking supplement) and 12(0.5%) hyponatremic ( < 134 mmol/L or taking supplement). Survivors with No CKD or CKD Grades 1-5 were 93.6%, 4.1%, 0.9%, 1.2%, 0.1%, and 0.1%, respectively. In multivariable analyses, non-Hispanic black race (OR = 2.19, 1.43-3.34), history of nephrectomy (OR = 2.74, (1.39- 5.41)), increased body mass index (BMI) (BMI 35-40 vs ≤ 25, OR = 2.36 (1.38-4.05), BMI ≥ 40 vs > 0-25 (OR = 2.15 (1.21-3.82)), history of treatment with ifosfamide (IFOS) (OR = 2.24 (1.23-4.06)), or cis-platinum (DDP) (OR = 1.89 (1.10-3.23)) were associated with CKD Grade 1-5 vs No CKD. age at RF evaluation ≥ 50 yrs vs ≥ 18-30 yrs (OR = 6.72 (1.06-42.79)), history of treatment with IFOS (OR = 7.23 (2.47-21.12)), or DDP (OR = 5.25 (2.14-12.85)) exposure were risk factors for CKD = Grade 3-5 vs No CKD. High-dose cyclophosphamide ( ≥ 1000 mg/m2/course) was not associated with CKD. Conclusions: CKD and abnormalities of electrolyte concentrations are infrequent among CCS. BMI, race/ethnicity, and treatment may be associated with CKD.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 10571
Renal function after treatment for childhood cancer.
10571 Background: Childhood cancer survivors (CCS) are exposed to nephrotoxic treatments. We assessed renal function (RF), and factors associated with chronic kidney disease (CKD) in a large cohort of long-term CCS unexposed to abdominal irradiation. Methods: We evaluated 2,314 SJLIFE participants ( > 10 years (yrs) post-diagnosis, age ≥ 18 yrs) measuring serum sodium, potassium, magnesium, urinalysis (hematuria ≥ 5 RBC/hpf; proteinuria ≥ 1+ protein), and estimated glomerular filtration rate (eGFR) using the CKD Epidemiology Collaboration (CKD-EPI) equation. CKD was defined according to the National Kidney Foundation Kidney Disease Outcome Quality Initiative. Logistic regression, adjusting for length of follow-up, was used to estimate odds ratios (ORs) and 95% confidence intervals (CI) for the association between demographic and clinical factors, and CKD. Results: 1110(48%) survivors were female. 1920(83%) were non-Hispanic white. Median age at diagnosis-6.9 yrs (interquartile range [IQR] = 3.2-12.6), median age at RF evaluation-31 yrs (IQR = 25.3-37.0), and median elapsed time from diagnosis to evaluation-23 yrs (IQR = 17.3-29.4). 70(3.0%) were hypokalemic ( < 3.4 mmol/L or taking supplement), 39(1.7%) hypomagnesemic ( < 1.3 meq/dL or taking supplement) and 12(0.5%) hyponatremic ( < 134 mmol/L or taking supplement). Survivors with No CKD or CKD Grades 1-5 were 93.6%, 4.1%, 0.9%, 1.2%, 0.1%, and 0.1%, respectively. In multivariable analyses, non-Hispanic black race (OR = 2.19, 1.43-3.34), history of nephrectomy (OR = 2.74, (1.39- 5.41)), increased body mass index (BMI) (BMI 35-40 vs ≤ 25, OR = 2.36 (1.38-4.05), BMI ≥ 40 vs > 0-25 (OR = 2.15 (1.21-3.82)), history of treatment with ifosfamide (IFOS) (OR = 2.24 (1.23-4.06)), or cis-platinum (DDP) (OR = 1.89 (1.10-3.23)) were associated with CKD Grade 1-5 vs No CKD. age at RF evaluation ≥ 50 yrs vs ≥ 18-30 yrs (OR = 6.72 (1.06-42.79)), history of treatment with IFOS (OR = 7.23 (2.47-21.12)), or DDP (OR = 5.25 (2.14-12.85)) exposure were risk factors for CKD = Grade 3-5 vs No CKD. High-dose cyclophosphamide ( ≥ 1000 mg/m2/course) was not associated with CKD. Conclusions: CKD and abnormalities of electrolyte concentrations are infrequent among CCS. BMI, race/ethnicity, and treatment may be associated with CKD.
- 1 January 2015
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 70 (1) , 28-29
American Society of Clinical Oncology Position Statement on Obesity and Cancer
- 1 January 2015
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 70 (1) , 28-29
American Society of Clinical Oncology Position Statement on Obesity and Cancer
- 1 April 2007
- Published by Annual Reviews in Annual Review of Public Health
- Vol. 28 (1) , 279-302
Adverse Late Effects of Childhood Cancer and Its Treatment on Health and Performance
More than 12,000 newly diagnosed cases of cancer occur each year in the United States among children ages 20 years or younger, and the current 5-year survival rate is near 80%. An estimated 228,000 among adults 47 years or younger and currently living in the United States had a diagnosis of cancer during childhood or adolescence. Here, we review long-term adverse effects of childhood cancer and its treatment with an emphasis on physical performance and health. We also briefly review existing guidelines that may be used to develop appropriate exercise and diet interventions for childhood cancer survivors. We suggest that there is a need for development of evidence-based, risk-based guidelines and interventions for health promotion among long-term childhood cancer survivors, particularly for those whose physical activity limitations interfere with chances for optimizing their bodies' potential in today's society.
- 1 April 2007
- Published by Annual Reviews in Annual Review of Public Health
- Vol. 28 (1) , 279-302
Adverse Late Effects of Childhood Cancer and Its Treatment on Health and Performance
More than 12,000 newly diagnosed cases of cancer occur each year in the United States among children ages 20 years or younger, and the current 5-year survival rate is near 80%. An estimated 228,000 among adults 47 years or younger and currently living in the United States had a diagnosis of cancer during childhood or adolescence. Here, we review long-term adverse effects of childhood cancer and its treatment with an emphasis on physical performance and health. We also briefly review existing guidelines that may be used to develop appropriate exercise and diet interventions for childhood cancer survivors. We suggest that there is a need for development of evidence-based, risk-based guidelines and interventions for health promotion among long-term childhood cancer survivors, particularly for those whose physical activity limitations interfere with chances for optimizing their bodies' potential in today's society.
- 7 November 2006
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 49 (7) , 975-981
Body composition, muscle strength deficits and mobility limitations in adult survivors of childhood acute lymphoblastic leukemia
Background: Chronicity of muscle weakness from cancer and its treatment may be problematic, particularly in those treated for cancer during childhood. We compared body composition, muscle strength, and mobility between 75 adult survivors of childhood acute lymphoblastic leukemia (ALL) and expected values based on population normative data.Methods: Subjects were young adults treated for childhood ALL between 1970 and 1986, selected randomly from participants in an ongoing study of cancer survivors. DeXA scans were performed to evaluate body composition, and myometry used to measure strength. Mobility was evaluated with the Timed Up and Go (TUG) and 2‐min walk (TMW). One sample t‐tests compared ALL survivors to population norms.Results: Males had 4.5% and females had 2.3% more body fat than expected (expected males 21.5%, females 36.0%). Males were 76.7 Newtons and females were 58.6 Newtons weaker in quadriceps strength than expected (expected males 569.87 N, females 464.67 N). Males walked 100.88 m and females walked 85.38 m less on the TMW (expected values: males 304.23 m, females 276.26 m), and took longer to complete the TUG (males 5.82 vs. 2.84 sec, females 5.88 vs. 3.00 sec) than expected. Treatment with cranial radiation and current growth hormone (GH) deficiency were associated with lower body weakness among females.Conclusions: Young adult survivors of childhood ALL have strength and mobility deficits. Decreased strength may reduce ability to participate in physical activity, perpetuating fitness deficits in survivors of childhood ALL. Pediatr Blood Cancer 2007;49:975–981.
- 7 November 2006
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 49 (7) , 975-981
Body composition, muscle strength deficits and mobility limitations in adult survivors of childhood acute lymphoblastic leukemia
Background: Chronicity of muscle weakness from cancer and its treatment may be problematic, particularly in those treated for cancer during childhood. We compared body composition, muscle strength, and mobility between 75 adult survivors of childhood acute lymphoblastic leukemia (ALL) and expected values based on population normative data.Methods: Subjects were young adults treated for childhood ALL between 1970 and 1986, selected randomly from participants in an ongoing study of cancer survivors. DeXA scans were performed to evaluate body composition, and myometry used to measure strength. Mobility was evaluated with the Timed Up and Go (TUG) and 2‐min walk (TMW). One sample t‐tests compared ALL survivors to population norms.Results: Males had 4.5% and females had 2.3% more body fat than expected (expected males 21.5%, females 36.0%). Males were 76.7 Newtons and females were 58.6 Newtons weaker in quadriceps strength than expected (expected males 569.87 N, females 464.67 N). Males walked 100.88 m and females walked 85.38 m less on the TMW (expected values: males 304.23 m, females 276.26 m), and took longer to complete the TUG (males 5.82 vs. 2.84 sec, females 5.88 vs. 3.00 sec) than expected. Treatment with cranial radiation and current growth hormone (GH) deficiency were associated with lower body weakness among females.Conclusions: Young adult survivors of childhood ALL have strength and mobility deficits. Decreased strength may reduce ability to participate in physical activity, perpetuating fitness deficits in survivors of childhood ALL. Pediatr Blood Cancer 2007;49:975–981.